June 2nd 2025
T-DXd plus pertuzumab significantly extended PFS (40.7 vs 26.9 months) in HER2+ metastatic breast cancer, suggesting a new frontline standard of care.
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Kentucky
View More
Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer—The Evolving Role of Antibody-Drug Conjugates
View More
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
23rd Annual School of Breast Oncology
November 6-8, 2025
Register Now!
Community Practice Connections™: Navigating Early-Stage HR+/HER2‒- Breast Cancer – Clinical Developments and Innovative Treatments
View More
Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
View More
The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference
View More
43rd Annual Miami Breast Cancer Conference®
March 5-8, 2026
Register Now!
Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer
View More
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
View More
Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment
View More
Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation
View More
Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer
View More
Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment
View More
Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
View More
Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Adjuvant T-DM1 Outperforms Trastuzumab in HER2-Positive Early Breast Cancer
February 12th 2025Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease after neoadjuvant therapy.
Read More
Durability and Intracranial Efficacy Observed With T-DXd in HER2+ MBC
January 13th 2025During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of metastatic HER2-positive breast cancer in the second article of a 2-part series.
Read More
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
December 13th 2024Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.
Read More
Study Reveals Encouraging Results in HER2+ Breast Cancer With Brain Mets
November 1st 2024Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis.
Read More
T-DXd Use in HER2+ Breast Cancer Influenced by Site of Metastases and AE Monitoring
October 21st 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.
Read More
Wei Assesses Role of TROP2 and HER2 Status in Treatment With Sacituzumab for ER+ mBC
September 26th 2024During an in-person Community Case Forum in partnership with the Rocky Mountain Oncology Society, Mei Wei, MD, discussed data from the TROPiCS-02 trial of sacituzumab govitecan in patients with metastatic breast cancer.
Read More
Overall Survival With Dato-DXd Fails to Meet Significance in Breast Cancer
September 23rd 2024Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer.
Read More
Dual HER2 Blockade Plus Ribociclib Offers Chemo-Free Option in HR+/HER2+ Breast Cancer
September 16th 2024Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib showed potential as a novel approach for patients with HR+/HER2+ breast cancer.
Read More
T-DXd Maintains QOL, Delays Pain Deterioration in HR+/HER2-Low/Ultralow MBC
September 15th 2024Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.
Read More